BIOLASE Receives ASTRUM Award at MDB Capital’s Bright Lights Conference 2011 Recognized for Innovation Leadership and the Development of Numerous Disruptive Technologies, Most Notably the Development of a New Surgical System to Cut Human Tissue in a Biological and Atraumatic Way IRVINE, CA — (Marketwire) — 05/11/11 — BIOLASE Technology, Inc. (NASDAQ: BLTI), the World’s leading dental laser manufacturer and distributor, today announced that it received the ASTRUM Award, presented by MDB Capital Group to Federico Pignatelli, Chairman and CEO, and Dmitri Boutoussov, Vice President of Engineering and Development, at the 2nd annual Bright Lights Conference at the Le Parker Meridien Hotel in New York City. BIOLASE was recognized for its innovation leadership and the development of numerous disruptive technologies measured by the highest Patent Application compound annual growth rate (CAGR) and number of patent applications on file and adjusted for Application Conversion Rate.
“BIOLASE stood out as the top company in its industry with the highest Patent Application CAGR and the highest number of patent applications on file, adjusted for Application Conversion Rate, and we are honored to recognize the Company’s achievements in driving IP as an asset class and the impact the Company is making on innovation in America,” commented Christopher A. Marlett, CEO of MDB Capital Group.
Pignatelli said, “Providing innovative and disruptive technologies that advance the practice of dentistry and medicine, leading to enhanced outcomes and more comfortable patient experiences, continues to be the focus at BIOLASE. We are especially enthusiastic with our development of a new surgical system to cut human tissue in a biological and atraumatic way. This development could revolutionize the way surgeons perform a broad range of procedures. This award is a testament to those efforts and serves as overdue recognition for our productive and inventive R&D teams in Irvine. We are honored to have been recognized by MDB as it relates to our extensive IP and we look forward to getting many additional technologies to market in the coming years.”
BIOLASE was selected from MDB’s 2011 group of “Best and Brightest” small-cap companies and advanced as one of the 40 public companies ranking in the 90th percentile for its respective technology leadership from more than 1,500 small-cap companies with granted U.S. patents, as rated by PatentVest, MDB’s proprietary IP business intelligence platform. The Bright Lights Conference is the only conference with an exclusive focus on publicly-traded companies with disruptive and market changing IP.
About BIOLASE Technology, Inc.
BIOLASE Technology, In c., the World’s leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company’s laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find
BIOLASE at http://www.biolase.com
Twitter at http://twitter.com/biolaseinc
YouTube at http://www.youtube.com/biolasevideos
Facebook at http://www.facebook.com/biolaseinc
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by ourmanagement. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” ”plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
